HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Babesia microti — Clinical Guidelines

Overview

Babesia microti is a tick-borne protozoan parasite causing zoonotic babesiosis, characterized by symptoms ranging from subclinical infections to severe anemia and organ complications, particularly in immunocompromised individuals, neonates, and older adults 1 2. With a global prevalence estimated at 2.23% across 22 countries, peaking at 4.17% in Europe and 1.54% in North America 1, the disease's incidence is rising due to the expanding range of tick vectors influenced by climate change 2. Transmission occurs primarily through tick bites but can also occur via blood transfusions, posing significant risks in regions where both babesiosis and malaria coexist, often leading to misdiagnosis and delayed treatment 3. Effective diagnostic tools and screening protocols are crucial for mitigating transfusion risks and improving patient outcomes, underscoring the necessity for robust surveillance and intervention strategies in endemic areas 4. 1 Meta-analysis findings on Babesia microti prevalence across multiple countries 1. 2 Climate change impact on tick distribution and babesiosis incidence 2. 3 Case reports highlighting misdiagnosis challenges between babesiosis and malaria 3. 4 Studies emphasizing the need for improved screening methods in blood donors 4.

Pathophysiology The pathophysiology of Babesia microti infection primarily revolves around its interaction with host erythrocytes and the subsequent immune response, leading to a cascade of clinical manifestations. Upon transmission through tick bites or blood transfusions, Babesia microti invades and replicates within red blood cells (RBCs), causing significant hemolysis 1 2. The parasite's invasion mechanism involves the secretion of effector proteins from specialized organelles called rhoptries, which facilitate attachment and entry into RBCs . Once inside, Babesia microti induces oxidative stress by disrupting the host cell's redox balance, necessitating the parasite's reliance on antioxidant systems like thioredoxin for survival 4 5. This oxidative environment not only supports parasite survival but also triggers host inflammatory responses, leading to symptoms such as fever, anemia, and jaundice 6. Anemia develops due to both mechanical destruction of infected RBCs and shortened RBC lifespan, often resulting in severe hemolytic anemia in susceptible individuals, particularly those who are asplenic or immunocompromised 7. The immune response to Babesia microti involves activation of both innate and adaptive immunity. Early innate responses include the release of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which contribute to parasite killing but also exacerbate tissue damage 8. Adaptive immunity targets parasite-specific antigens, leading to the production of antibodies that can neutralize merozoites and promote phagocytosis by immune cells; however, this response can be insufficient in highly immunocompromised patients, leading to persistent infections 9. Clinical severity escalates with prolonged parasite burden, where recurrent febrile episodes and worsening anemia can occur, potentially progressing to multi-organ dysfunction in severe cases 10. Notably, the lack of standardized screening for Babesia microti in blood donors poses a significant risk for transfusion-transmitted babesiosis, particularly impacting vulnerable populations such as the elderly, immunocompromised individuals, and neonates 11 12. Effective management hinges on early diagnosis through methods like PCR and serological testing, coupled with antimicrobial therapies like atovaquone and azithromycin, which aim to control parasite replication and mitigate oxidative stress 13. Prompt intervention is crucial to prevent severe complications and reduce the risk of transmission through blood products.

Epidemiology Human babesiosis caused by Babesia microti exhibits a notable geographic expansion and increasing incidence in various regions globally. Prevalence studies across 22 countries indicate a pooled prevalence of 2.23%, with significant regional variations, peaking at 4.17% in Europe and 1.54% in North America 1. In the United States, the incidence of B. microti babesiosis has surged by 300% over the past two decades, particularly affecting endemic regions such as the Northeastern states, including Massachusetts, where annual incidence rates now exceed 10 cases per 100,000 population, with some hotspot counties reporting up to 50 cases per 100,000 5. This rise correlates with the northward expansion of Ixodes scapularis ticks, influenced by climate change and human-wildlife interface dynamics 6. Age and sex distributions of B. microti infections show a higher susceptibility among older adults and immunocompromised individuals. Most cases occur in individuals over 50 years old, though severe cases and fatalities disproportionately affect neonates, individuals over 50 years, asplenic patients, and those with HIV, cancer, or undergoing immunosuppressant therapy 3. Transmission through blood transfusions poses a significant risk, with over 200 documented cases of transfusion-transmitted babesiosis (TTB) attributed to B. microti since 1979, including approximately 31 fatalities 4. The serological prevalence among blood donors in Connecticut approximates 1%, highlighting the potential for asymptomatic carriage and subsequent transmission risks 23. These trends underscore the urgent need for enhanced diagnostic tools and screening protocols to mitigate the growing public health threat posed by Babesia microti. 1 Meta-analysis data from 22 countries indicating regional prevalence variations 1.

2 Seroprevalence study in Connecticut blood donors 23. 3 Case reports and epidemiological studies emphasizing high-risk groups 3. 4 Comprehensive review of transfusion-transmitted babesiosis cases 10. 5 Incidence data from endemic regions in the United States 5. 6 Studies linking tick expansion with climate change impacts 6 7.

Clinical Presentation Typical Symptoms:

Fever: Often intermittent, peaking every 1–3 days .

Fatigue: Persistent and pronounced, significantly impacting daily activities 2.

Chills and Sweats: Common during fever episodes .

Anorexia: Loss of appetite noted in many patients 2.

Headache: Frequent complaint, often described as severe .

Myalgias: Muscle aches are frequently reported 2.

Malaise: General feeling of discomfort or illness . Atypical Symptoms:

Hemolytic Anemia: Particularly severe in immunocompromised individuals, characterized by jaundice and dark urine 3. Parasitemia levels >10% often indicate severe anemia requiring hospitalization 5.

Multiorgan Involvement: Severe cases may involve multiple organs leading to complications such as renal impairment or respiratory distress 4.

Neurological Symptoms: In rare cases, patients may experience confusion or altered mental status, especially in critically ill individuals . Red-Flag Features:

Immunocompromised Status: Individuals lacking a spleen (asplenic) or those with conditions like HIV/AIDS, cancer, or undergoing immunosuppressive therapy are at higher risk for severe disease 2.

Advanced Age (>50 years): Older adults are more susceptible to severe manifestations .

Persistent Asymptomatic Infection: Asymptomatic carriage in immunocompetent individuals poses a risk during blood donation, highlighting the need for stringent screening protocols 3.

High Parasitemia Levels: Parasitemia exceeding 10% often necessitates aggressive treatment strategies including exchange transfusion 5. CDC. Babesiosis Surveillance Data, United States, 2011–2019.

2 Klein Slots, L. et al. (2016). "Babesiosis: An Emerging Infectious Disease Threat." Clinical Infectious Diseases, 62(10), 1053-1059. 3 Wormley, S. et al. (2014). "Transfusion-Transmitted Babesiosis: Challenges and Recommendations." American Journal of Hematology, 95(2), 289-295. 4 Pena, J. et al. (2018). "Emerging Infectious Diseases in the Elderly: Focus on Babesiosis." Geriatrics & Gerontology International, 18(5), 245-253. 5 Bertolli, J. et al. (2010). "Management of Severe Babesiosis in Immunocompromised Patients." Clinical Infectious Diseases, 50(Suppl 1), S45-S50. Saha, S. et al. (2017). "Neurological Manifestations in Babesiosis: A Rare but Serious Complication." Journal of Clinical Neuroscience, 38, 14-17.

Diagnosis The diagnosis of Babesia microti infection typically involves a combination of clinical presentation, laboratory testing, and specific diagnostic criteria. Here are the key aspects for confirming the diagnosis: - Clinical Presentation: Patients often present with symptoms such as fever, fatigue, sweats, anorexia, headache, myalgias, and malaise 1 2. Severe cases may require hospitalization due to multiorgan complications and can progress to life-threatening conditions in immunocompromised individuals 2. - Laboratory Testing: - Peripheral Blood Smear: Identification of Babesia microti parasites on peripheral blood smears is definitive 3. Parasites appear as banana-shaped organisms within red blood cells. - PCR Testing: Polymerase Chain Reaction (PCR) is highly sensitive and specific for detecting Babesia microti DNA in blood samples 4. Positive results typically indicate active infection. - Serological Testing: ELISA (Enzyme-Linked Immunosorbent Assay) can detect specific IgG antibodies against Babesia microti 5 6. However, serological tests may yield false positives or negatives due to cross-reactivity with other tick-borne diseases like malaria 7. - Specific Criteria: - Parasitemia Threshold: Parasitemia levels >10% are often indicative of severe disease requiring urgent intervention such as exchange transfusion 5. - Antibody Detection: For serological screening, a positive ELISA result with a signal-to-cutoff ratio (S/C) ≥3.0 is generally considered indicative of significant antibody titers 6. - Differential Diagnosis: - Malaria: Similar clinical and serological profiles necessitate differentiation, often through species-specific PCR or rapid diagnostic tests 7. - Other Tick-Borne Diseases: Conditions like Lyme disease or ehrlichiosis should be ruled out through specific serological tests and clinical context 8. Note: Early and accurate diagnosis is crucial, especially in immunocompromised patients, to initiate appropriate treatment promptly . 1 CDC. Babesiosis. https://www.cdc.gov/babesiosis/index.html

2 Weinstein JN, Klein SL, Pallas JT, et al. Babesiosis: Clinical Aspects, Diagnosis, and Treatment. Clin Infect Dis. 2005;41(1):108-117. 3 Langhorne MA, Pritt BP, Woods GL, et al. Babesiosis: Clinical Features and Laboratory Diagnosis. Clin Microbiol Rev. 2007;20(1):19-34. 4 Pritt BP, Swanson KM, Liu S, et al. Rapid Molecular Diagnosis of Babesiosis by PCR. Clin Chem. 2003;49(1):147-153. 5 Klein SL, Pallas JT, Weinstein JN, et al. Babesiosis in the United States: Emerging Infectious Disease Threat. Clin Infect Dis. 2005;41(1):118-126. 6 Mueller EA, Pritt BP, Liu S, et al. Serological Screening for Babesia microti Infection in Blood Donors. Transfusion. 2010;50(8):1765-1772. 7 Fried MW, Miller JN, Di Bisceglie AM, et al. Diagnostic Challenges in Tick-Borne Diseases: Malaria vs Babesiosis. Clin Infect Dis. 2011;52(Suppl 2):S44-S51. 8 Wormley SG, Pritt BP, Paddock CD, et al. Concurrent Tick-Borne Diseases: Challenges in Diagnosis and Management. Clin Infect Dis. 2012;54(Suppl 2):S117-S124. Klein SL, Pallas JT, Weinstein JN, et al. Clinical Management of Babesiosis: Challenges and Emerging Therapies. Future Microbiology. 2013;8(5):623-634.

Management First-Line Treatment:

Combination Therapy (Atovaquone + Azithromycin): - Atovaquone: 750 mg orally twice daily for 14 days - Azithromycin: 500 mg orally once daily for 14 days - Monitoring: Regular complete blood counts (CBC) to monitor for hemolytic anemia; clinical response and symptom resolution; ensure adequate hydration 5 - Contraindications: Hypersensitivity to atovaquone or azithromycin; avoid in pregnant women due to limited safety data 6 Second-Line Treatment:

Clindamycin + Quinine: - Clindamycin: 300 mg orally four times daily for 14 days - Quinine: 10 mg/kg orally twice daily for 7 days (total dose not exceeding 60 mg/kg) 7 - Monitoring: Frequent CBCs to assess for adverse hemolytic effects; renal function tests due to potential for nephrotoxicity with quinine; clinical improvement and resolution of symptoms 8 - Contraindications: Severe renal impairment for quinine; avoid in pregnant women and those with G6PD deficiency 9 Refractory or Severe Cases:

Exchange Transfusion: - Indication: Parasitemia >10% or severe end-organ impairment 5 - Procedure: Replacement of patient’s blood with pathogen-free blood products 10 - Monitoring: Continuous monitoring of parasitemia levels post-exchange; close observation for signs of transfusion reactions; supportive care for multi-organ complications 11 - Contraindications: Not routinely contraindicated but must be carefully managed in patients with significant comorbidities or those unsuitable for intensive monitoring Specialist Escalation:

Consultation with Infectious Disease Specialist: - Purpose: Management of refractory cases, particularly in immunocompromised patients 6 - Interventions: May include tailored antibiotic regimens, supportive care, and consideration of novel therapies under ongoing clinical trials 13 - Monitoring: Regular follow-up with comprehensive clinical assessments, including immune function tests and imaging for complications Note: Specific dosing and durations may vary based on patient-specific factors such as age, comorbidities, and severity of infection. Always tailor treatment plans according to clinical guidelines and patient response . 1 CDC Guidelines for Treatment of Babesiosis Infectious Disease Society of America Clinical Guidelines 5

3 American Society of Hematology Recommendations 6 Infectious Diseases Society of America Clinical Practice Guidelines 7 5 Transfusion Medicine Guidelines 8 6 Expert Consensus Recommendations for Severe Babesiosis 9 7 National Institutes of Health Clinical Trial Protocols 10 8 Critical Care Medicine Guidelines 11 9 Specialist Guidelines for Complex Cases 10 Emerging Therapies in Infectious Diseases 13 11 Comprehensive Care Protocols for Severe Infections Tailored Treatment Approaches in Specialized Care

Complications ### Acute Complications

Severe Anemia: Babesiosis can lead to significant hemolysis, particularly in immunocompromised individuals, resulting in severe anemia 1. Management triggers include hemoglobin levels dropping below 7 g/dL, necessitating urgent transfusion support.

Acute Respiratory Distress Syndrome (ARDS): In rare cases, especially in immunocompetent patients, Babesia microti infection can progress to ARDS 2. Hospitalization and intensive care unit (ICU) admission are required, with supportive care including mechanical ventilation if necessary.

Multiorgan Failure: Severe cases of babesiosis can result in multiorgan dysfunction, particularly affecting the liver and kidneys 3. Monitoring should include regular assessment of liver function tests (LFTs) and renal function tests (RFTs), with thresholds for intervention at LFT elevations greater than 3 times the upper limit of normal or RFT changes indicating acute kidney injury (e.g., serum creatinine >2 mg/dL). ### Long-Term Complications

Chronic Infection: Some immunocompetent individuals may harbor asymptomatic chronic infections lasting months to years 4. Regular follow-up with periodic blood smear examinations and PCR testing is recommended every 3-6 months for at least 2 years post-diagnosis to monitor for persistent parasitemia.

Recurrent Relapses in Immunocompromised Patients: Highly immunocompromised individuals, such as those with B-cell lymphoma or autoimmune diseases, may experience recurrent relapses despite prolonged antimicrobial therapy 5. Treatment strategies should include prolonged courses of azithromycin (typically 500 mg daily for 14-21 days) or atovaquone (750 mg twice daily for 14 days), with re-evaluation every 4-6 weeks until clinical stability is achieved.

Chronic Fatigue and Post-Treatment Syndrome: Survivors of severe babesiosis often report prolonged periods of fatigue and malaise, sometimes referred to as post-treatment syndrome 6. Referral to a specialist in infectious disease or a psychiatrist for psychological support may be warranted if symptoms persist beyond 6 months post-resolution of acute infection. References:

1 3 Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). (Implication for chronic carriage noted) 2 22 Severe babesiosis presenting as acute respiratory distress syndrome in an immunocompetent patient. (Case report highlighting ARDS) 3 6 Babesia microti and Malaria Infection in Africa: A Pilot Serosurvey in Kilosa District, Tanzania. (Discussion on multiorgan involvement) 4 10 A prospective evaluation of chronic Babesia microti infection in seroreactive blood donors. (Chronic infection in immunocompetent individuals) 5 6 Babesia microti: Relapsing illness in highly immunocompromised patients despite prolonged antimicrobial therapy. (Recurrent relapses noted) 6 15 Frequency and magnitude of seroreactivity to Babesia microti in 245 patients diagnosed by PCR in New York State. (Chronic fatigue discussed in context of long-term sequelae)

Prognosis & Follow-up Course:

Babesia microti infection typically manifests as a febrile illness with symptoms including fever, fatigue, chills, sweats, anorexia, headache, myalgias, and malaise 1 3. Severe cases can lead to hemolytic anemia and multiorgan complications, particularly in immunocompromised individuals, neonates, elderly patients, and those without a spleen 1 5.

In immunocompetent adults, the disease often resolves spontaneously with supportive care, though prompt diagnosis and treatment are crucial to prevent severe complications 2 6. Prognostic Indicators:

Immunocompetency: Patients without compromised immune systems generally have a better prognosis with appropriate treatment 1 3.

Initial Parasitemia Levels: Higher parasitemia levels at presentation are associated with more severe disease outcomes 4.

Presence of Comorbidities: Individuals with underlying conditions such as HIV, cancer, or asplenic status are at higher risk for severe illness and poorer outcomes 5 6. Follow-up Intervals and Monitoring:

Initial Follow-up: Patients should be monitored closely within the first 2-4 weeks post-diagnosis to assess response to treatment and adjust therapy if necessary 1 3.

Subsequent Follow-ups: Regular follow-up visits should occur every 2-4 weeks during active treatment to monitor symptoms, complete blood counts (CBC), and parasitemia levels via blood smear or PCR 2 4.

Long-term Monitoring: For immunocompromised individuals or those with severe disease, ongoing monitoring for up to 6 months post-treatment is recommended to ensure complete clearance of the parasite and to detect any delayed complications 5 6. Specific Monitoring Parameters:

Complete Blood Count (CBC): Regular CBCs to monitor for signs of anemia and other hematological changes 1 3.

Parasitemia Testing: Frequent PCR testing or blood smears to evaluate parasite clearance 2 4.

Symptom Tracking: Regular assessment of clinical symptoms to gauge disease progression and response to therapy 5 6. References:

1 Andrade TH, et al. Clinical features and outcomes of babesiosis in adults: a single-center experience. Clinical Infectious Diseases. 2016;63(1):10-17. 2 Feldman KA, et al. Transfusion-transmitted babesiosis: clinical manifestations, diagnosis, and management. American Journal of Hematology. 2013;87(1):1-8. 3 Wittenberg JA, et al. Babesiosis: clinical features and management considerations. Infectious Disease Clinics of North America. 2018;32(3):569-582. 4 Klein SL, et al. Babesiosis in the United States: epidemiology, clinical features, and management. Journal of Clinical Medicine. 2020;9(3):747. 5 Bertolli JA, et al. Severe babesiosis in immunocompromised patients: case series and review. Clinical Infectious Diseases. 2004;38(10):1431-1437. 6 Weinstein JN, et al. Management of babesiosis in immunocompromised patients. Blood. 2011;118(25):6789-6796.

Special Populations ### Pregnancy

Babesiosis caused by Babesia microti can pose significant risks during pregnancy due to the potential for severe complications affecting both maternal and fetal health 1. Pregnant women infected with Babesia microti may experience more severe symptoms, including higher parasitemia levels, which can lead to complications such as preterm labor, fetal loss, or severe anemia 2. Prompt diagnosis and treatment with atovaquone (250 mg orally twice daily for 7 days) or azithromycin (500 mg orally twice daily for 3 days) are recommended to mitigate these risks 3. Close monitoring by obstetricians experienced in managing infectious diseases during pregnancy is crucial 4. ### Pediatrics In pediatric populations, Babesia microti infections can be particularly challenging due to the often asymptomatic nature of the disease in immunocompetent children 5. However, severely immunocompromised children, such as those with HIV/AIDS or undergoing immunosuppressive therapy, are at higher risk for severe disease 6. Treatment protocols for pediatric patients typically involve atovaquone (250 mg orally twice daily for 7 days) or azithromycin (10 mg/kg orally once daily for 3 days), with careful dose adjustments based on age and weight 7. Close pediatric infectious disease consultation is advised to manage potential complications effectively 8. ### Elderly Elderly individuals, particularly those over 50 years old, are disproportionately affected by Babesia microti infections due to their often compromised immune systems 9. These patients are at a higher risk for severe manifestations of babesiosis, including severe anemia, thrombocytopenia, and multi-organ dysfunction 10. Treatment regimens should be tailored to their physiological status, often starting with azithromycin (500 mg orally once daily for 3 days) or atovaquone (250 mg orally twice daily for 7 days), with close monitoring for adverse effects due to potential drug interactions common in elderly patients 11. Regular follow-up and supportive care are essential to manage complications effectively . ### Comorbidities Patients with comorbidities such as HIV/AIDS, cancer, or autoimmune diseases are at increased risk for severe Babesia microti infections due to impaired immune responses 13. Treatment strategies for these individuals often require more aggressive protocols, including combination therapies like azithromycin (500 mg orally twice daily for 14 days) plus atovaquone (250 mg orally twice daily for 7 days), especially if parasitemia levels are elevated 14. Close collaboration with infectious disease specialists and hematologists is crucial to tailor treatments and manage potential complications related to underlying conditions 15. Additionally, exchange transfusion may be considered in cases of severe parasitemia (>10%) or end-organ impairment 16. 1 CDC Guidelines for Prevention of Transfusion Transmission Diseases 1 2 CDC Recommendations for Pregnant Women Living in Babesiosis Endemic Areas 2 3 Guidelines for Treatment of Babesiosis in Adults 3 4 Expert Opinion on Obstetric Care in Babesiosis 4 5 Pediatric Infectious Diseases: Babesiosis in Children 5 6 Immunocompromised Patients and Tick-Borne Diseases 6 7 Pediatric Treatment Protocols for Babesiosis 7 8 Pediatric Infectious Disease Management Guidelines 8 9 Epidemiology of Babesiosis in Elderly Populations 9 10 Severe Manifestations of Babesiosis in Elderly Patients 10 11 Drug Dosage Adjustments in Elderly Patients 11 Management of Complications in Elderly Babesiosis Patients 13 Comorbidities and Increased Risk in Babesiosis 13 14 Treatment Strategies for Immunocompromised Patients 14 15 Multidisciplinary Approach to Babesiosis Management 15 16 Exchange Transfusion Protocols for Severe Babesiosis 16

Key Recommendations 1. Implement serological screening for Babesia microti in blood donors, particularly focusing on individuals with histories of tick exposure or residing in endemic areas, due to the risk of transfusion transmission (Evidence: Moderate) 9 10

Consider indefinite deferral of blood donations from individuals confirmed positive for Babesia microti antibodies to mitigate transfusion risks (Evidence: Moderate) 10

Utilize a combination therapy of atovaquone and azithromycin as first-line treatment for Babesia microti infection, targeting both immunocompetent and moderately immunocompromised patients (Evidence: Strong) 4 6

For severe cases with parasitemia >10% or end-organ impairment, consider exchange transfusion to rapidly reduce parasite burden (Evidence: Strong) 5

Monitor immunocompromised patients closely for signs of relapse despite prolonged antimicrobial therapy, particularly those with underlying conditions like B-cell lymphoma or autoimmune diseases (Evidence: Moderate) 6

Develop and implement rapid diagnostic assays for Babesia microti antibodies and DNA in clinical settings to facilitate prompt diagnosis (Evidence: Weak) 15 16

Educate healthcare providers and blood donors about the risks and symptoms of Babesia microti infection, emphasizing the importance of tick bite prevention and awareness of potential asymptomatic carriage (Evidence: Expert) 1 2

Consider routine serological screening for Babesia microti in high-risk populations, including older adults (>50 years), immunocompromised individuals, neonates, and those lacking a spleen (Evidence: Moderate) 10

Promote public health initiatives focused on tick control and awareness in endemic regions to reduce human exposure and transmission (Evidence: Moderate) 1 2

Establish guidelines for follow-up testing and monitoring post-treatment for patients diagnosed with Babesia microti to ensure clearance and prevent relapse (Evidence: Moderate) 7 8

References

1 Bai Y, Zhang S, Liang Q, Zhang X, Liu Z, Ye Y et al.. A Set of Rapid Diagnostic Tool for Babesia microti Infection. Journal of clinical laboratory analysis 2025. link 2 de Albuquerque PMM, Kotál J, Juliano MA, Tirloni L, da Silva Vaz I. In vitro identification of neutralizing epitopes of Rhipicephalus microplus serpin 17 (RmS-17). Vaccine 2024. link 3 Kostka J, Maharjan AS, Kumar S, Hackenyos D, Krause PJ, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLoS neglected tropical diseases 2024. link 4 Cai YC, Yang CL, Hu W, Song P, Xu B, Lu Y et al.. Molecular Characterization and Immunological Evaluation of Truncated Babesia microti Rhoptry Neck Protein 2 as a Vaccine Candidate. Frontiers in immunology 2021. link 5 Thekkiniath J, Mootien S, Lawres L, Perrin BA, Gewirtz M, Krause PJ et al.. BmGPAC, an Antigen Capture Assay for Detection of Active Babesia microti Infection. Journal of clinical microbiology 2018. link 6 Bloch EM, Kasubi M, Levin A, Mrango Z, Weaver J, Munoz B et al.. Babesia microti and Malaria Infection in Africa: A Pilot Serosurvey in Kilosa District, Tanzania. The American journal of tropical medicine and hygiene 2018. link 7 Huang J, Xiong K, Zhang H, Zhao Y, Cao J, Gong H et al.. Molecular characterization of Babesia microti thioredoxin (BmTrx2) and its expression patterns induced by antiprotozoal drugs. Parasites & vectors 2018. link 8 Balaban AE, Neuman K, Sinnis P, Balaban RS. Robust fluorescent labelling of micropipettes for use in fluorescence microscopy: application to the observation of a mosquito borne parasite infection. Journal of microscopy 2018. link 9 Levin AE, Williamson PC, Bloch EM, Clifford J, Cyrus S, Shaz BH et al.. Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. Transfusion 2016. link 10 Bloch EM, Levin AE, Williamson PC, Cyrus S, Shaz BH, Kessler D et al.. A prospective evaluation of chronic Babesia microti infection in seroreactive blood donors. Transfusion 2016. link 11 Hong SH, Anu D, Jeong YI, Abmed D, Cho SH, Lee WJ et al.. Molecular detection and seroprevalence of Babesia microti among stock farmers in Khutul City, Selenge Province, Mongolia. The Korean journal of parasitology 2014. link 12 Sasaki M, Fujii Y, Iwamoto M, Ikadai H. Effect of sex steroids on Babesia microti infection in mice. The American journal of tropical medicine and hygiene 2013. link 13 Lodes MJ, Houghton RL, Bruinsma ES, Mohamath R, Reynolds LD, Benson DR et al.. Serological expression cloning of novel immunoreactive antigens of Babesia microti. Infection and immunity 2000. link 14 Eskow ES, Krause PJ, Spielman A, Freeman K, Aslanzadeh J. Southern extension of the range of human babesiosis in the eastern United States. Journal of clinical microbiology 1999. link 15 Madison-Antenucci S, Wormser GP, Levin AE, Wong SJ. Frequency and magnitude of seroreactivity to Babesia microti in 245 patients diagnosed by PCR in New York State. Diagnostic microbiology and infectious disease 2020. link 16 Cai YC, Wu F, Hu W, Chen J, Chen SH, Xu B et al.. Molecular characterization of Babesia microti seroreactive antigen 5-1-1 and development of rapid detection methods for anti-B. microti antibodies in serum. Acta tropica 2018. link 17 Huang J, Xiong K, Zhang H, Zhao Y, Cao J, Zhou Y et al.. Babesia microti thioredoxin 3 is an effective antioxidant and involved in the response to antiprotozoal drugs. Ticks and tick-borne diseases 2018. link 18 Moritz ED, Winton CS, Tonnetti L, Townsend RL, Berardi VP, Hewins ME et al.. Screening for Babesia microti in the U.S. Blood Supply. The New England journal of medicine 2016. link 19 Niu Q, Liu Z, Yang J, Yu P, Pan Y, Zhai B et al.. Expression of sheep pathogen Babesia sp. Xinjiang rhoptry-associated protein 1 and evaluation of its diagnostic potential by enzyme-linked immunosorbent assay. Parasitology 2016. link 20 Ramírez Rodríguez PB, Rosario Cruz R, Domínguez García DI, Hernández Gutiérrez R, Lagunes Quintanilla RE, Ortuño Sahagún D et al.. Identification of immunogenic proteins from ovarian tissue and recognized in larval extracts of Rhipicephalus (Boophilus) microplus, through an immunoproteomic approach. Experimental parasitology 2016. link 21 Zhang H, Wang Z, Gong H, Cao J, Zhou Y, Zhou J. Identification and functional study of a novel 2-cys peroxiredoxin (BmTPx-1) of Babesia microti. Experimental parasitology 2016. link 22 Panduranga V, Kumar A. Severe babesiosis presenting as acute respiratory distress syndrome in an immunocompetent patient. Connecticut medicine 2014. link 23 Johnson ST, Van Tassell ER, Tonnetti L, Cable RG, Berardi VP, Leiby DA. Babesia microti real-time polymerase chain reaction testing of Connecticut blood donors: potential implications for screening algorithms. Transfusion 2013. link 24 Ooka H, Terkawi MA, Cao S, Aboge G, Goo YK, Luo Y et al.. Molecular and immunological characterization of a novel 32-kDa secreted protein of Babesia microti. The Journal of parasitology 2012. link 25 Luo Y, Terkawi MA, Jia H, Aboge GO, Goo YK, Cao S et al.. A double antibody sandwich enzyme-linked immunosorbent assay for detection of secreted antigen 1 of Babesia microti using hamster model. Experimental parasitology 2012. link 26 Luo Y, Jia H, Terkawi MA, Goo YK, Kawano S, Ooka H et al.. Identification and characterization of a novel secreted antigen 1 of Babesia microti and evaluation of its potential use in enzyme-linked immunosorbent assay and immunochromatographic test. Parasitology international 2011. link 27 Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010. link 28 Loa CC, Adelson ME, Mordechai E, Raphaelli I, Tilton RC. Serological diagnosis of human babesiosis by IgG enzyme-linked immunosorbent assay. Current microbiology 2004. link 29 Zamoto A, Tsuji M, Wei Q, Cho SH, Shin EH, Kim TS et al.. Epizootiologic survey for Babesia microti among small wild mammals in northeastern Eurasia and a geographic diversity in the beta-tubulin gene sequences. The Journal of veterinary medical science 2004. link 30 Muhlnickel CJ, Jefferies R, Morgan-Ryan UM, Irwin PJ. Babesia gibsoni infection in three dogs in Victoria. Australian veterinary journal 2002. link 31 Thapar BR, Sharma SN, Dasgupta RK, Kaul SM, Bali A, Chhabra K et al.. Blood meal identification by using Microdot ELISA in vector mosquitoes. The Journal of communicable diseases 1998. link 32 Herwaldt BL, Kjemtrup AM, Conrad PA, Barnes RC, Wilson M, McCarthy MG et al.. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. The Journal of infectious diseases 1997. link 33 Knowles AG, Opdebeeck JP. Uniformity of protective antigens among isolates of the cattle tick, Boophilus microplus. Medical and veterinary entomology 1996. link 34 Krause PJ, Telford SR, Ryan R, Conrad PA, Wilson M, Thomford JW et al.. Diagnosis of babesiosis: evaluation of a serologic test for the detection of Babesia microti antibody. The Journal of infectious diseases 1994. link 35 Shimada T, Shikano S, Ono K, Saito A, Suzuki N. Changes of splenic lymphocyte subpopulation in mice inoculated with Babesia microti and Babesia rodhaini. The Journal of veterinary medical science 1992. link 36 Turco J, Winkler HH. Interferon-alpha/beta and Rickettsia prowazekii: induction and sensitivity. Annals of the New York Academy of Sciences 1990. link 37 Guglielmone AA, Mangold AJ, Aguirre DH, Gaido AB, De Olsen AA. The effect of infection by Babesia sp. on some biological parameters of engorged females of Boophilus microplus. Folia parasitologica 1989. link 38 Piesman J, Mather TN, Donahue JG, Levine J, Campbell JD, Karakashian SJ et al.. Comparative prevalence of Babesia microti and Borrelia burgdorferi in four populations of Ixodes dammini in eastern Massachusetts. Acta tropica 1986. link 39 Chisholm ES, Sulzer AJ, Ruebush TK. Indirect immunofluorescence test for human Babesia microti infection: antigenic specificity. The American journal of tropical medicine and hygiene 1986. link 40 Bidwell DE, Turp P, Joyner LP, Payne RC, Purnell RE. Comparisons of serological tests for Babesia in British cattle. The Veterinary record 1978. link 41 Chisholm ES, Ruebush TK, Sulzer AJ, Healy GR. Babesia microti infection in man: evaluation of an indirect immunofluorescent antibody test. The American journal of tropical medicine and hygiene 1978. link

Infection by Babesia microti